Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | OAT | P04181 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.33 |
| ▸ | ITGAV | P06756 | 4/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.32 |
| ▸ | ITGAL | P20701 | 3/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.32 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079678 | 0.80 | — | — | |
| Trifluoroacetic Acid SCHEMBL31425255 | 0.79 | OAT (0.38) | OATGABRR1 | |
| Trifluoroacetic Acid SCHEMBL16967035 | 0.78 | OAT (0.33) | OAT | |
| Hydrochloric Acid SCHEMBL2278643 | 0.78 | CRBN (0.50) | CRBNMAP3K14 | |
| Bromide SCHEMBL1086848 | 0.78 | CRBN (0.50) | CRBNMAP3K14 | |
| Trifluoroacetic Acid SCHEMBL1967871 | 0.76 | CRBN (0.55) | CRBNITGB1ITGB3ITGAVITGA4 | |
| Trifluoroacetic Acid SCHEMBL31320778 | 0.73 | OAT (0.37) | OATGABRR1 | |
| Trifluoroacetic Acid SCHEMBL31637517 | 0.73 | L3MBTL1 (0.33) | CRBNITGB1ITGA5ITGB3ITGAV | |
| Trifluoroacetic Acid SCHEMBL3025153 | 0.73 | OAT (0.36) | OATALDH1A1GABRR1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL28310891 | 0.72 | CRBN (0.59) | CRBNITGB1ITGB3ITGAVITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2386565-A2 | Compounds and methods to inhibit or augment an inflammatory response | Cambridge Enterprise Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | disclosed |
| EP-1141011-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | NEORX CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042071-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CCL2, CCL11, CCL5 | CRBN 3747/4885OAT 3754/4885MAP3K14 1318/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | CRBN 3483/4885OAT 2398/4885MAP3K14 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.